Information from www.pcodr.ca
|Province||Status||Date of Decision||Funding Criteria|
|Alberta||Funded||October 19, 2012||Treatment of BRAF V600 mutation – positive resectable or metastatic melanoma|
|British Columbia||Funded||October 1, 2012||Unresectable stage III or stage IV melanoma BRAF V600 mutation-positive; ECOG 0-2; life expectancy of at least 3 months; 18 years and older (for patients younger than 18 years old, CAP will review the eligibility on a case-by-case basis); adequate hematological, hepatic and renal function; if brain metastases are present, they must have been previously treated and be stable. A BCCA “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment|
|Manitoba||Funded||September 24, 2012||
|New Brunswick||Funded||September 11, 2013||
Approval Period: 6 months
Recommended Dose: 960 mg twice daily until disease progression or development of
|Nova Scotia||Funded||March 4, 2013||
|Ontario||Funded||August 31, 2012||For the first line treatment of patients with BRAF V600 mutation-positive unresectable stage IIIC or IV melanoma or metastatic melanoma in patients meeting the following criteria:
For the second (2nd) line treatment of patients with BRAF V600 mutation-positive unresectable stage IIIC or IV melanoma OR for patients with metastatic melanoma who have progressed after receiving treatment in the first line setting in patients who meet the following criteria:
Patients meeting the following exclusion criteria will not be funded:
Recommended Dose: 960 mg twice daily until disease progression or development of unacceptable toxicity requiring discontinuation of vemurafenib.
Renewals** will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of vemurafenib.
*Definition of Stable – No metastases to the central nervous system (unless successfully treated for 3 months or more as demonstrated by no progression and with no requirement for corticosteroids).
**Please note that renewals must be accompanied by a letter from the physician outlining radiological and clinical benefit from treatment that supports that the drug should be continued AND this must include verification that the disease has not progressed while on vemurafenib.
|Prince Edward Island||Under provincial consideration|
|Saskatchewan||Funded||September 4, 2012||Melanoma – Advanced: